The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Other Investors | Alive

About Crystax Pharmaceuticals

Crystax Pharmaceuticals is a structure-based drug discovery company. The company identify and develop new lead compounds by a combination of structural and biophysical techniques that accelerate the process of drug discovery and bring higher quality molecules to the market.

Crystax Pharmaceuticals Headquarter Location

Barcelona Science Park Josep Samitier 1-5



Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

  • When was Crystax Pharmaceuticals founded?

    Crystax Pharmaceuticals was founded in 2002.

  • What is Crystax Pharmaceuticals's latest funding round?

    Crystax Pharmaceuticals's latest funding round is Other Investors.

  • Who are the investors of Crystax Pharmaceuticals?

    Investors of Crystax Pharmaceuticals include Empresa Nacional de Innovacion, BCN Telecom and Invertec.

  • Who are Crystax Pharmaceuticals's competitors?

    Competitors of Crystax Pharmaceuticals include Sequoia Sciences, MerLion Pharmaceuticals, MicuRx Pharmaceuticals, Achaogen, Melinta Therapeutics and 15 more.

You May Also Like

Trana Discovery Logo
Trana Discovery

Trana Discovery, a drug discovery technology company, aims to help its partners find classes of drugs for the treatment of serious viral, fungal, and bacterial infectious diseases. The technology identifies compounds that work through a mechanism of action: inhibition of the target pathogen's ability to use transfer RNA (tRNA) essential for protein synthesis or replication. The use of Trana Discovery technology can unlock the value " scientific, human, and financial " hidden in drug compound libraries, expedite the discovery of drugs, and provide opportunities for exclusive rights to drug classes.

Active Pass Pharmaceuticals

Active Pass is a Canadian biotechnology company that is engaging in genomic-based drug discovery and is developing drugs that inhibit ABC transporters. ABC or (ATP binding cassette) is a term that describes the interconnected group of molecular engines or pumps that function as a transportation system which moves compounds across the biological membranes. These ABCs are very closely associated with human diseases like Alzheimer's disease, diabetes, asthma, and hypertension. The Active Pass management team is an accomplished group with experience in many aspects of drug discovery and development. Besides employing full time pharmaceutical development professionals, Active Pass has made wise use of a group of several key partnerships with different pharmaceutical groups. The company cultivates these partnerships in order to access new capabilities or expertise to advance the company's own technologies. More specifically, these partnerships include the Vaccines and Infectious Diseases Organization as well as the National Institute of Health). The company hopes to add new personnel to cover emerging areas of emphasis like clinical and regulatory affairs, business development and finance as they grow.


GNI's "gene network" technology is based on a combination of wet lab work and lots of computing power to figure out how the 30,000-plus protein-making genes in the human genome interact. Its primary product is a drug discovery engine to quickly identify genes for drug development, as well as figure out which genes are affected by a given drug.

Aquapharm Logo

Aquapharm, founded in 2000, is a marine natural products company that uses marine bacteria, a very large untapped reservoir of natural products, and fungi to produce and commercialise functional food compounds and pharmaceuticals. The STF invested as part of a £1.9m funding round to develop Aquapharm's anti-microbial drug discovery business and to conduct pilot-scale manufacture and apply for Food status from the EU and FDA to allow sales into European and US markets.

Nereus Pharmaceuticals

Nereus Pharmaceuticals is a drug discovery and development company pursuing sources of chemical diversity through identifying drug candidates derived from marine microbes. With unmatched expertise in marine microbiology and integrated technologies to identify and synthesize biologically active compounds, the company's two oncology drug candidates are in Phase I clinical trials. Plinabulin (NPI-2358), a tumor vascular disrupting agent, is being evaluated for solid tumors, and a proteasome inhibitor NPI-0052 is being developed for solid tumors, lymphomas and multiple myeloma. Nereus' discovery portfolio also includes additional drug candidates for oncology, infectious diseases, and inflammation.


ConjuGon is focused on developing fundamentally new products to eliminate bacterial infections. ConjuGon was founded in 2001, to develop and commercialize a novel, conjugation-based antibacterial technology discovered at the University of Wisconsin-Madison. The primary clinical purpose of products based on this technology will be to prevent and eliminate antibiotic-resistant, bacterial infections of the skin and soft tissues including traumatic injury, surgical, and burn wounds. The company has also in-licensed from Baylor University, an innovative technology to prevent catheter-associated urinary tract infections. Presently, ConjuGon performs most of its Research and Development operations at its corporate headquarters in Madison, WI and contracts with leading pharmaceutical, manufacturing, clinical research and regulatory experts nationwide to advance its products.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.